Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
1 finding from 1 review
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: prevention of ulcer · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Resource implications (e.g. cost of incontinence management methods) · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of daytime urinary incontinence · children aged 5 to 16 years with daytime urinary incontinence
Voiding education with uroflow feedback and urotherapy showed no clear difference in resolution of daytime urinary incontinence at 6 to 12 months after 6… compared with urotherapy alone (low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measurement of volume of incontinent episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found